Corbus Pharmaceuticals Updates Executive Employment Agreements and Protections

Corbus Pharmaceuticals ( (CRBP) ) has provided an announcement.

On April 15, 2026, Corbus Pharmaceuticals entered into amended and restated employment agreements with Chief Executive Officer Yuval Cohen and Chief Financial Officer Sean Moran, setting new two-year terms through April 15, 2028 with increased clarity around salary, bonuses and equity eligibility. The updated contracts introduce detailed severance, non-compete and non-solicitation provisions, including enhanced cash, bonus and equity-vesting protections in connection with terminations without cause or for good reason, particularly around change-in-control events, underscoring the company’s focus on leadership stability and alignment with shareholder interests.

Under Cohen’s sixth amended agreement, he will continue as CEO with a $673,625 base salary, bonus eligibility of up to 60% of base pay, potential discretionary equity awards and severance protections that scale to as much as 24 months of salary, extended COBRA coverage, accelerated vesting and a multiple of target bonus during a change-in-control period. Moran’s seventh amended deal sets a $501,273 base salary, up to 40% target bonus and similar equity eligibility, with non-compete and non-solicitation covenants and severance benefits that can rise to 18 months of salary, extended COBRA coverage, full equity acceleration and a target-level bonus if his role ends without cause or for good reason in connection with a change in control.

The most recent analyst rating on (CRBP) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

Spark’s Take on CRBP Stock

According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.

The score is held back mainly by weak financial performance (no meaningful revenue, worsening 2025 losses and cash burn) and limited valuation support (negative P/E, no dividend). These are partly offset by a constructive technical trend and favorable corporate developments, including FDA alignment for CRB-701 and continued clinical trial progress.

To see Spark’s full report on CRBP stock, click here.

More about Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics. The company operates in the pharmaceutical and life sciences industry, where experienced leadership and long-term executive retention are considered important to support clinical development, regulatory strategy and potential commercialization efforts.

Average Trading Volume: 194,750

Technical Sentiment Signal: Sell

Current Market Cap: $177.4M

See more data about CRBP stock on TipRanks’ Stock Analysis page.